Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Pfs Hiding'

Pfs Hiding published presentations and documents on DocSlides.

Median PFS: 2.6 months (95% CI, 1.7-3.5)
Median PFS: 2.6 months (95% CI, 1.7-3.5)
by ceila
Median PFS: 1.4 months (95% CI, 1.2-1.6) . Median ...
2014 Oklahoma Business Summit
2014 Oklahoma Business Summit
by marina-yarberry
Sarah Roberts, Inasmuch Foundation, Program Offic...
Thierry Le Chevalier, MD
Thierry Le Chevalier, MD
by yoshiko-marsland
How . d. o International Regulatory Groups View C...
Partnerships for Success
Partnerships for Success
by test
Creating Positive School Experiences And Develop...
Ray Jones
Ray Jones
by danika-pritchard
Director of Solutions Architecture and Field Enab...
Blinded Sample Size Re-estimation in a Phase III Study Inve
Blinded Sample Size Re-estimation in a Phase III Study Inve
by luanne-stotts
David Morgan (King’s College, London / Consulta...
Thierry Le Chevalier, MD
Thierry Le Chevalier, MD
by aaron
How . d. o . International Regulatory Groups View...
Applying “Pay for Success” Social Impact Finance to Ear
Applying “Pay for Success” Social Impact Finance to Ear
by luanne-stotts
Janis Dubno, Voices for Utah Children. Andrea Phi...
Her-2 negative MBC
Her-2 negative MBC
by conchita-marotz
10/25/2016. Objectives. General principles. Endoc...
Interpretation of the Great Plains Polygonal Fault
Interpretation of the Great Plains Polygonal Fault
by luanne-stotts
Andy St-Onge, Calgary geophysicist@shaw.ca. (i) S...
Btk inhibition in Mantle cell Lymphoma & CLL
Btk inhibition in Mantle cell Lymphoma & CLL
by test
Simon Rule. Professor of Clinical . Haematology. ...
BELLE-3: A Phase III Study of
BELLE-3: A Phase III Study of
by faustina-dinatale
Buparlisib. and . Fulvestrant. in Postmenopausa...
Managing Advanced Renal Cell
Managing Advanced Renal Cell
by debby-jeon
Carcinoma: Balancing . Efficacy with Quality of L...
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com
by olivia-moreira
Jointly provided by ...
End-points utilized in
End-points utilized in
by marina-yarberry
End-points utilized in breast cancer clinical ...
Game Plan Trends in ovarian cancer
Game Plan Trends in ovarian cancer
by alexa-scheidler
Diagnostic work-up. Treatment. The most commonly ...
Nouveautés dans le CBNPC métastatique
Nouveautés dans le CBNPC métastatique
by vizettan
Celine Mascaux, MD, . PhD. Multidisciplinary . Onc...
Presentation
Presentation
by wang
pfs-full-vlSchema Taxo Fullwith capitalpfs-fullPre...
2022 Spring Oncology Conference
2022 Spring Oncology Conference
by byrne
Evolving Treatment Strategies. for CLL/SLL and MCL...
Update on Diagnosis and Treatments
Update on Diagnosis and Treatments
by joanne
of Multiple Myeloma. Kenneth C. Anderson, M.D.. J...
ESMO 2021 (Virtual) Congress Report
ESMO 2021 (Virtual) Congress Report
by SnuggleBug
Lung and gastrointestinal cancers. Slide numbers. ...
Considerations for Optimizing Transplant in Multiple Myeloma Patient Management
Considerations for Optimizing Transplant in Multiple Myeloma Patient Management
by TravelingSoulmate
PARAMESWARAN HARI MD. MEDICAL COLLEGE OF WISCONSIN...
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
by naomi
David Morgan (King’s College, London / Consultan...
Summary 2011 Founded 2010
Summary 2011 Founded 2010
by eliza
in Houston. Vision: To be the leader in the develo...
YIR On Demand Lung Benjamin Levy, MD 
YIR On Demand Lung Benjamin Levy, MD 
by jovita
Assistant Professor. Johns Hopkins School of Medic...
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref
by willow
Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-V...
Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m
Concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in m
by felicity
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor...
End-points utilized in breast cancer
End-points utilized in breast cancer
by evelyn
clinical . trials - Discussion. Novartis Oncology...
Pay for Success: Innovative Financing to Improve Child Outcomes
Pay for Success: Innovative Financing to Improve Child Outcomes
by dominic513
Jennifer Tschantz; Early Childhood Research to Pra...
Company profi leProject name: Songwe Hill Rare Earths ProjectP
Company profi leProject name: Songwe Hill Rare Earths ProjectP
by min-jolicoeur
PFS well advanced, favourable topography, simple w...
Multiple Myeloma – Is It Now Curable?
Multiple Myeloma – Is It Now Curable?
by celsa-spraggs
Andrzej . J. . Jakubowiak, MD, PhD. Director, Mye...
Impact of Imatinib interruption & duration of prior Hyd
Impact of Imatinib interruption & duration of prior Hyd
by pamella-moone
Raafat. R. Abdel-. Malek. , MD, FRCR. Ass. Prof ...
Treatment of
Treatment of
by natalia-silvester
Biliary. Cancers. Abby B. Siegel, MD, MS . Colum...
Product Labels – Defending the Use of Processed Foods
Product Labels – Defending the Use of Processed Foods
by min-jolicoeur
Michigan Department of Education. School Nutritio...
Series:
Series:
by lois-ondreau
From Tax Preparer to Financial Planner: The Road ...
MEK Inhibitors and their potential role in relapsed NSCLC
MEK Inhibitors and their potential role in relapsed NSCLC
by debby-jeon
Ranee Mehra, MD. Fox Chase Cancer Center. Philade...
Department of GI Medical Oncology
Department of GI Medical Oncology
by danika-pritchard
Does . the New EPOC trial . eliminate. . Anti. -...
Update on transplant-ineligible patients:
Update on transplant-ineligible patients:
by trish-goza
Which . regimens are best?. Suzanne Lentzsch MD, ...
Chee Lee,
Chee Lee,
by olivia-moreira
MBBS (Hons), . MMedSci. (. Clin. . Epid. ), . M...
ASCO Update 2012:
ASCO Update 2012:
by tatyana-admore
Gastrointestinal Malignancies. Thomas J. Semrad M...